Saturday, 9 May 2020

Investigational COVID-19 Convalescent Plasma

The
U.S. FDA has produced a new guidance document: “Investigational COVID-19
Convalescent Plasma”.

FDA
is issuing this guidance to provide recommendations to health care providers
and investigators on the administration and study of investigational
convalescent plasma collected from individuals who have recovered from COVID-19
(COVID-19 convalescent plasma) during the public health emergency. The guidance also provides recommendations to
blood establishments on the collection of COVID-19 convalescent plasma.